a public good project by the
Synthesis
Company
of California

© 2026

David M. Briere | doi.page

0 works0 citations0 h-index

David M. Briere

Bristol-Myers Squibb (Germany)(DE)Bristol-Myers Squibb (United States)(US)Mirati Therapeutics (United States)(US)

Publications by Year

Research Areas

Cancer-related gene regulation, Prostate Cancer Treatment and Research, Biochemical and Molecular Research, Protein Kinase Regulation and GTPase Signaling, Lung Cancer Treatments and Mutations

Most-Cited Works

→ The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients(2019)1,249 cited
→ Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor(2021)661 cited
→ Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer(2020)572 cited
→ Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor(2022)475 cited
→ MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP -Deleted Cancer(2023)172 cited
→ The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy

(2021)

161 cited

→ Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models(2017)147 cited

→ The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy(2017)143 cited

→ Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP -Deleted Cancers(2022)140 cited

→ Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity(2018)106 cited